Acadia Healthcare Company, Inc.

Acadia Healthcare Company, Inc. (ACHC) Market Cap

Acadia Healthcare Company, Inc. has a market capitalization of $2.53B.

Financials based on reported quarter end 2025-12-31

Price: $27.44

-0.40 (-1.44%)

Market Cap: 2.53B

NASDAQ · time unavailable

CEO: Debra K. Osteen

Sector: Healthcare

Industry: Medical - Care Facilities

IPO Date: 1994-03-04

Website: https://www.acadiahealthcare.com

Acadia Healthcare Company, Inc. (ACHC) - Company Information

Market Cap: 2.53B · Sector: Healthcare

Acadia Healthcare Company, Inc. provides behavioral healthcare services in the United States and Puerto Rico. The company offers behavioral healthcare services to its patients in various settings, including inpatient psychiatric hospitals, specialty treatment facilities, residential treatment centers, and outpatient clinics. As of March 31, 2022, it operated a network of 238 behavioral healthcare facilities with approximately 10,600 beds. The company was founded in 2005 and is headquartered in Franklin, Tennessee.

Analyst Sentiment

70%
Buy

Based on 25 ratings

Analyst 1Y Forecast: $23.43

Average target (based on 4 sources)

Consensus Price Target

Low

$14

Median

$22

High

$31

Average

$21

Downside: -22.3%

Price & Moving Averages

Loading chart...

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 ACADIA HEALTHCARE COMPANY INC (ACHC) — Investment Overview

🧩 Business Model Overview

Acadia Healthcare Company Inc. (ACHC) operates as one of the largest standalone pure-play behavioral health companies in the United States. The company owns and operates a diversified portfolio of facilities specializing in inpatient, residential, partial hospitalization, and outpatient behavioral healthcare services. Its service offering addresses various mental health and addiction treatment needs, including psychiatric care for adults, adolescents, and children, substance use disorder (SUD) services, eating disorder treatments, and specialized therapeutic programs. The company’s operations span urban, suburban, and rural markets across the U.S., with a facility network designed to serve both privately insured and publicly covered patients. Acadia’s model involves the ownership or long-term lease of healthcare facilities, through which it delivers evidence-based clinical programs administered by licensed professionals. The company’s mission is to provide accessible, high-quality behavioral health care, positioning it as a key player amid growing national awareness of mental health issues.

💰 Revenue Streams & Monetisation Model

Acadia’s revenue is predominantly generated from patient care services delivered through its inpatient and outpatient facilities. The company’s patient population includes individuals covered by commercial insurance, Medicaid, Medicare, military insurance, and private pay. Payment models are dictated by a mix of negotiated rates with managed care organizations, government program reimbursement schedules, and cash payments. Key revenue streams include: - **Inpatient Services:** The largest revenue contributor, encompassing acute psychiatric treatment, detoxification, and residential care. - **Outpatient & Partial Hospitalization:** Comprising day programs, intensive outpatient therapies, and ongoing counseling services. - **Specialty Programs:** Including youth-focused care, eating disorder clinics, and unique therapeutic interventions. - **Public Sector Contracts:** The company frequently works with state and local governments, corrections systems, and VA programs for dedicated service provision. Acadia’s diversified payer mix provides some insulation against reimbursement trends and volume fluctuations in any single segment. The company continually seeks to optimize its payer and program mix to enhance margins and ROI across its network.

🧠 Competitive Advantages & Market Positioning

Acadia holds distinctive competitive advantages driven by its national scale, specialization, and breadth of clinical offerings. Several key factors underpin its positioning: - **Scale and Network Density:** Acadia’s footprints in multiple states and its ability to serve broad geographies bolster brand recognition and referral relationships with physician groups, hospitals, payers, and government agencies. - **Expertise in Regulatory Compliance:** The behavioral health space is highly regulated, and Acadia benefits from deep institutional expertise in navigating complex federal and state regulations, licensure requirements, and evolving reimbursement models. - **Accredited, Diverse Programs:** The company operates a wide range of evidence-based treatment protocols, enabling it to cater to the diverse needs of populations ranging from adolescents to seniors, urban to rural. - **Barriers to Entry:** Significant capital investment, regulatory complexity, and the requirement for extensive clinical and administrative expertise serve as barriers for new entrants. While the behavioral health sector includes both nonprofit and for-profit competitors, Acadia’s strategy focuses on clinical quality, facility upgrades, and robust local partnerships, further cementing its leadership.

🚀 Multi-Year Growth Drivers

Multiple structural and company-specific drivers support Acadia’s long-term growth prospects: - **Increasing Demand for Behavioral Health Services:** Societal recognition of mental health and addiction as critical public health issues, combined with stigma reduction and expanded insurance coverage, drives rising patient volumes. - **Favorable Demographics and Policy Tailwinds:** An aging population, high adolescent mental health needs, and governmental focus on expanding access to behavioral health drive persistent demand. - **Network Expansion and M&A:** Acadia’s scalable platform supports organic growth through de novo clinic openings and facility expansions, alongside a disciplined strategy of acquiring high-quality behavioral health assets. - **Service Line Diversification:** Expansion into ancillary and outpatient services, telehealth, and innovative care delivery models provides new revenue channels and increases patient lifetime value. - **Managed Care Penetration:** Enhanced negotiation leverage and direct payer contracting ability strengthen margins while broadening access to covered populations. Collectively, these growth vectors position Acadia to capitalize on both increased utilization rates and higher per-patient reimbursement over time.

⚠ Risk Factors to Monitor

Investors should remain mindful of several inherent and external risk factors: - **Reimbursement Pressure:** Shifts in government and private insurance reimbursement methodologies, including rate cuts or increased scrutiny of mental health claims, can impact revenue and profitability. - **Regulatory and Compliance Exposure:** The company is subject to frequent changes in healthcare legislation, licensing requirements, and accreditation standards; non-compliance can result in fines, operational constraints, or reputational harm. - **Workforce Challenges:** Recruitment, retention, and cost inflation in clinical staff, especially acute amid national shortages of behavioral health professionals, can pressure margins and constrain growth. - **Competitive Landscape:** Both established and emergent for-profit/nonprofit institutions, hospital systems, and telemedicine entrants continuously invest in behavioral health, challenging Acadia’s market share in select geographies. - **Litigation and Liability Risk:** Given the nature of behavioral healthcare, exposure to professional liability claims and regulatory investigations is ongoing.

📊 Valuation & Market View

Acadia Healthcare typically garners valuation multiples in line with premium healthcare providers, driven by its high-mission, non-cyclical service offering, recurring patient flows, and strong demand drivers. Key valuation metrics monitored by the market include enterprise value to EBITDA, revenue multiples, and free cash flow yield. Acadia’s strategy emphasizes disciplined capital allocation, re-investment in facility infrastructure, and balance sheet optimization to support growth and shareholder value. Market sentiment around Acadia reflects optimism regarding secular demand for behavioral healthcare, but investors often calibrate positions based on evolving reimbursement landscapes, execution of growth initiatives, and resilience of profit margins. Comparisons are regularly drawn with other behavioral health operators, diversified hospital chains, and outpatient service providers to benchmark operational and financial performance.

🔍 Investment Takeaway

Acadia Healthcare stands as a significant, pure-play opportunity on the frontlines of expanding behavioral health demand in the United States. Its robust national presence, diversified facility network, and proven management team position the company to benefit from enduring secular trends and evolving healthcare needs. Core strengths in regulatory compliance, payer relations, and service line innovation underpin competitive advantages, while potential risks reside in reimbursement volatility and workforce constraints. For long-term investors seeking exposure to the intersection of healthcare, demographics, and policy evolution—particularly with a focus on behavioral health—Acadia Healthcare represents a strategically well-placed operator. Prudent monitoring of execution against growth strategies, margin sustainability, and evolving public health trends remains essential to realizing full investment potential.

⚠ AI-generated — informational only. Validate using filings before investing.

Fundamentals Overview

Loading fundamentals overview...

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2025-12-31

"In the quarter ending December 31, 2025, ACHC reported revenue of $821.5 million, with a significant net loss of $1.18 billion, translating to an EPS of -$13.02. Free cash flow stands at -$86.3 million. Year-over-year growth data is not provided, but the substantial net loss indicates significant challenges. Growth appears stagnant as revenue growth data is absent and the net loss heavily impacts profitability. Free cash flow was negative, signaling cash management issues, coupled with an inability to cover operational expenses as indicated by negative operating cash flow. The company holds assets worth $5.53 billion against liabilities of $3.39 billion, maintaining a debt/equity ratio that demands attention with net debt at $2.51 billion. There were no dividends or stock buybacks reported, impacting shareholder return potential. Analysts’ sentiment reflects caution with a consensus price target of $18.36, significantly below recent highs, indicating potential undervaluation but also risk. Overall, the company faces substantial performance challenges with a cautious outlook from the market."

Revenue Growth

Neutral

Stable but no significant growth figures reported. Revenue stagnation raises concerns.

Profitability

Neutral

Operating margins are negative with significant net loss, heavily impacting EPS.

Cash Flow Quality

Neutral

Negative free cash flow and operating cash flow indicate pressure on liquidity.

Leverage & Balance Sheet

Fair

Balanced assets and liabilities, but substantial net debt presents financial constraints.

Shareholder Returns

Neutral

No dividends or buybacks, limiting direct returns to shareholders.

Analyst Sentiment & Valuation

Caution

Market sentiment is cautious with a consensus price target reflecting both risk and potential value.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Management’s tone is constructive—demand is “very strong,” and the business model is expected to revert to “normal course” growth as bed additions stabilize. They also emphasize operational discipline and a data-driven approach (quality dashboards with 50+ measures) to speed escalation and reduce misses. However, the Q&A reveals specific, measurable operational headwinds that constrain 2026: New York Medicaid policy is quantified as a ~$25m-$30m annual EBITDA hit and is embedded as a ~350 bps headwind to same-facility volume growth, driving footprint rationalization (2 leased facility closures). Execution risk in ramping new facilities remains tangible: management points to licensure and “billing tie-in” processes as the common gating factors, implying delays can translate directly into slower occupancy monetization. Additional regulatory staffing pressure in California (ratios pushed to June 1) carries an embedded ~$4m EBITDA cost. Analysts pressing on ramp pacing and portfolio restructuring met with reassurance but not with new timing precision on margin unlock pace beyond a broad 5-year window.

AI IconGrowth Catalysts

  • Demand stability; management reiterates no change to the industry growth algorithm (low-to-mid single digit volume growth + low-to-mid single digit pricing gains).
  • Operating leverage from ramping facilities opened in 2023-2025 (core EBITDA growth driver per analyst bridge).
  • Continued bed adds: guidance for 400-600 new beds in 2026; management states incremental EBITDA from new facilities (2023-2026 openings) exceeds $200 million and should be realized within a 5-year window.

Business Development

  • 2025 JV openings: Henry Ford (MI), Geisinger (PA), Ascension (TX), ECU Health (NC), Fairview (MN).
  • 2026 expected JV facilities: Tufts Medicine, Methodist Health, Orlando Health.

AI IconFinancial Highlights

  • Q4 2025 revenue: $821.5m (+6.1% YoY); Adjusted EBITDA: $99.8m.
  • Q4 2025 reserve adjustment: $52.7m benefit to professional & general liability reserves (aligned to Dec 2, 2025 updated guidance).
  • Q4 same-facility revenue growth: +4.4% YoY, driven by +1.3% revenue per patient day and +3.1% patient days.
  • Q4 start-up losses: $12.8m (vs. $11.2m in Q4 2024). Closed facility costs: $3.6m net operating costs.
  • FY 2025 revenue: $3.31b (+5% YoY), slightly above $3.28b-$3.3b guidance range; FY adjusted EBITDA: $608.9m near upper end of $601m-$611m range.
  • FY 2025 CapEx: $572m total (nearly $50m favorable to prior guidance).
  • Net leverage: ~4.0x adjusted EBITDA (Dec 31, 2025). Liquidity: $133.2m cash + ~$595m available under $1.0b revolver.
  • 2026 guidance: revenue $3.37b-$3.45b; adjusted EBITDA $575m-$610m; adjusted EPS $1.30-$1.55.
  • 2026 same-facility volume growth: 0% to +1% with an approximate 350 bps headwind from New York Medicaid changes (noted as a key offset).
  • 2026 pricing assumption: +2% to +3% same-facility revenue per patient day; includes Medicaid supplemental payment decrease.
  • Regulatory programs awaiting approval: at least $22m EBITDA benefit if approved in 2026 (guidance excludes unapproved programs).
  • Start-up losses guidance: $47m-$53m (vs. $56m prior year); weighted ~60% in first half.
  • Free cash flow: positive expected in 2026; CapEx decline to $255m-$280m.

AI IconCapital Funding

  • CapEx: $93m in Q4; $572m for FY 2025; guided 2026 CapEx $255m-$280m.
  • Balance sheet: $133.2m cash and cash equivalents; ~$595m remaining availability on $1.0b revolving credit facility; net leverage ~4x adjusted EBITDA.

AI IconStrategy & Ops

  • Operational discipline emphasis: tighter operating focus and faster escalation; reviewing leadership depth and layers of operational supervision.
  • Facility ramp hurdle identified in Q&A: common themes tied to opening new hospitals—licensure and “billing tie-in”/ability to bill the incoming patient flow (not patient demand).
  • 2026 planning process adjusted for successful execution on 2026 openings.

AI IconMarket Outlook

  • 2026 same-facility volume growth: 0% to +1%, with ~350 bps headwind from New York Medicaid changes.
  • 2026 CapEx guidance: $255m-$280m; positive free cash flow expected.
  • First quarter 2026 outlook: revenue $820m-$830m; adjusted EBITDA $130m-$137m; start-up losses ~$14m; $11m out of period supplemental payments; severe weather impact ~$3.7m.

AI IconRisks & Headwinds

  • New York Medicaid outlier: state no longer allows Medicaid patients to receive care in out-of-state facilities; estimated $25m-$30m annual EBITDA impact; 2026 same-facility volume headwind of ~350 bps. Operational response: consolidating footprint and closing 2 leased specialty facilities; actively backfilling occupancy.
  • California staffing ratios: nursing staffing requirements phase-in pushed from Jan 31 to June 1; embedded $4m EBITDA impact in 2026 guidance (cost increase at the margin, not a staffing shortage).
  • Managed Medicaid/authorization pressure: management states length of stay is generally stable, but New York Medicaid patients historically stayed longer, creating an anticipated 2026 length-of-stay impact (directional but not quantified in transcript).
  • Professional liability / med mal: PLGL expense was a 2025 headwind; management says claims are consistent with December expectation and guidance held for 2026 (no new bps/amount provided beyond 2025 context).
  • Ramp risk / execution risk in new facilities: delays can come from licensure and billing tie-ins across state processes; management frames these as gating processes rather than demand.

Sentiment: MIXED

Note: This summary was synthesized by AI from the ACHC Q4 2025 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

Loading financial data and tables...
📁

SEC Filings (ACHC)

© 2026 Stock Market Info — Acadia Healthcare Company, Inc. (ACHC) Financial Profile